The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic ...

The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

Funded by investors such as Flagship and General Catalyst, the AI startup claims its platform will help scientists speed up ...

Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...

Findings from a pair of studies in tough-to-treat hypertension establish Mineralys’ drug as a “derisked, almost-commercial ...